DGX Price Prediction Next Week
Technical Analysis: DGX shows a bullish trend in recent trading sessions, with the stock closing at $171 on February 21, 2025. The price has formed higher lows and higher highs.
News Sentiment Analysis:
- Recent insider selling activity by SVP & General Counsel selling 604 shares
- Mixed institutional sentiment with 377 investors increasing positions while 410 reducing
- High rating (93%) from Validea's Multi-Factor Investor model, indicating strong fundamentals
- Multiple analysts have raised price targets:
- Piper Sandler: $180 (from $165)
- Truist: $182 (from $172)
- Baird: $189 (from $184)
- Barclays: $175 (from $168)
Price Prediction for Next Week: Based on technical indicators and analyst sentiment:
- Support level: $169
- Resistance level: $175
- Target price range: $172-176
Expected price movements:
- Monday: Opening around $171.50
- Mid-week: Testing $173-174 range
- End of week: Likely to settle around $175
Trading Recommendation: BUY Rationale:
- Multiple analyst upgrades
- Strong technical momentum
- High institutional quality score
- Price targets from major firms suggest 5-10% upside potential
Entry point: $171-172 Stop loss: $168 Take profit: $175
DGX Similar Chart Price Prediction
The price of DGX is predicted to go up 11.25%, based on the high correlation periods with VIPS. The similarity of these two price pattern on the periods is 98.17%.
DGX
VIPS
Up: 11.25%Similarity: 98.17%
DGX Revenue Forecast
DGX EPS Forecast
DGX FAQs
What is bull’s view on DGX?
What is bear's view on DGX?
What is DGX revenue forecast for next quarter？
What is DGX eps forecast for next quarter？
DGX VS S&P500
Advances in technology and personalized medicine are increasing the number of complex esoteric and gene-based tests available to patients. These tests generally carry a higher profit margin for Quest.
Quest has been actively seeking out hospital-outreach programs to roll up. These acquisitions offer very attractive economics to Quest.
Quest's web-based physician portal, Care360, organizes patient records and lab testing information in the same database. Doctors using Care360 are more likely to refer their patients to Quest's facilities.
DGX Analyst's Forecast
Stephanie Davis
Barclays
Hold
2025-01-31
Price Target
$168 → $175
Upside
+7.3%
Barclays raised the firm's price target on Quest Diagnostics to $175 from $168 and keeps an Equal Weight rating on the shares. The company reported a solid quarter and guidance, which implies recent utilization and revenue trends remain stable, the analyst tells investors in a research note.
Michael Cherny
Leerink Partners
Hold → Buy
2025-01-06
Price Target
$135 → $174
Upside
+14.27%
Derik De Bruin
B of A Securities
Strong Buy
2024-12-13
Price Target
$179 → $182
Upside
+17.42%
